董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Koh Boon Hwee Chairman of the Board 74 50.26万 4.70 2025-11-17
Padraig McDonnell President and Chief Executive Officer and Director 54 327.29万 1.25 2025-11-17
Daniel K. Podolsky Director 71 35.76万 未持股 2025-11-17
Mala Anand Director 57 33.18万 1.27 2025-11-17
Otis W. Brawley Director 65 34.27万 未持股 2025-11-17
George A. Scangos Director 77 36.76万 1.79 2025-11-17
Mikael Dolsten Director 66 35.76万 0.28 2025-11-17
Dow R. Wilson Director 66 37.26万 未持股 2025-11-17
Sue H. Rataj Director 67 35.76万 2.66 2025-11-17

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Padraig McDonnell President and Chief Executive Officer and Director 54 327.29万 1.25 2025-11-17
Rodney Gonsalves Vice President, Corporate Controller and Principal Accounting Officer 60 未披露 未持股 2025-11-17
Simon May Senior Vice President, President Diagnostic and Genomics Group 53 未披露 未持股 2025-11-17
Bret DiMarco Senior Vice President, Agilent and Chief Legal Officer and Secretary 57 未披露 未持股 2025-11-17
Jonah Kirkwood Senior Vice President, Agilent and Chief Commercial Officer, Commercial Organization 45 未披露 未持股 2025-11-17
Angelica A. Reimann Senior Vice President, Agilent and President, Agilent CrossLab Group 55 未披露 未持股 2025-11-17
Mike Zhang Senior Vice President, Agilent and President, Applied Markets Group 50 未披露 未持股 2025-11-17
Adam S. Elinoff Senior Vice President and Chief Financial Officer and Principal Financial Officer 48 未披露 未持股 2025-11-17

董事简历

中英对照 |  中文 |  英文
Koh Boon Hwee

Koh Boon Hwee,他担任一个私人股本基金--信任资本基金II开曼有限公司的管理合伙人。2009年1月以来,他担任向阳科技有限公司的非执行主席。此前,从2005年7月到2009年1月,他担任执行董事长兼首席执行官。2010年4月以来,他曾担任杨协成有限公司的非执行董事长。2011年2月以来,担任Rippledot资本顾问私人有限公司的非执行主席。2013年4月以来,担任远东果园有限公司的非执行主席。自2002年2月至2009年8月,他曾担任立通有限公司执行董事。2006年1月至2010年4月任期间,担任星展银行有限公司的主席。从2001年7月至2005年12月,新加坡航空公司主席。从1992年4月至2001年8月,担任新加坡电信的主席。他在其亚太地区的惠普公司工作了十四年。在向阳科技、瑞声科技、立通有限公司、星展银行、新加坡航空公司和新加坡电信担任多个高级职位,这是他拥有很多强有力的领导能力以及操作经验。此外,他在亚太地区拥有丰富的经验,者给董事会带来了知识和见解。他在安捷伦及其前身--惠普有很多经验,在安捷伦董事会9年多以及在惠普14年。


Koh Boon Hwee,has served as the non-Executive Chairperson of Agilent Technologies, Inc. Board since March 2017. As of January 2023, Mr. Koh is the non-Executive Chairman of the Singapore Exchange Ltd. He has been the managing partner of Altara Ventures Pte. Ltd., a venture capital fund, since December 2011. Mr. Koh has served as the non-Executive Chairperson of Sunningdale Tech Ltd., a privately held company, since April 2021. He served as the non-Executive Chairperson of Sunningdale Tech Ltd., a public company, from January 2009 to March 2021 and served as its Executive Chairperson and Chief Executive Officer from July 2005 to January 2009. He served as the non-Executive Chairperson of Far East Orchard Ltd. from April 2013 to April 2022; served as the non-Executive Chairperson of Yeo Hiap Seng Ltd. from April 2010 to December 2019; as Executive Director of MediaRing Limited from February 2002 to August 2009; Chairperson of DBS Bank Ltd. from January 2006 to April 2010; Chairperson of Singapore Airlines from July 2001 to December 2005 and Chairperson of Singapore Telecom from April 1992 to August 2001. Mr. Koh spent fourteen years with Hewlett-Packard Company in its Asia Pacific region.
Koh Boon Hwee,他担任一个私人股本基金--信任资本基金II开曼有限公司的管理合伙人。2009年1月以来,他担任向阳科技有限公司的非执行主席。此前,从2005年7月到2009年1月,他担任执行董事长兼首席执行官。2010年4月以来,他曾担任杨协成有限公司的非执行董事长。2011年2月以来,担任Rippledot资本顾问私人有限公司的非执行主席。2013年4月以来,担任远东果园有限公司的非执行主席。自2002年2月至2009年8月,他曾担任立通有限公司执行董事。2006年1月至2010年4月任期间,担任星展银行有限公司的主席。从2001年7月至2005年12月,新加坡航空公司主席。从1992年4月至2001年8月,担任新加坡电信的主席。他在其亚太地区的惠普公司工作了十四年。在向阳科技、瑞声科技、立通有限公司、星展银行、新加坡航空公司和新加坡电信担任多个高级职位,这是他拥有很多强有力的领导能力以及操作经验。此外,他在亚太地区拥有丰富的经验,者给董事会带来了知识和见解。他在安捷伦及其前身--惠普有很多经验,在安捷伦董事会9年多以及在惠普14年。
Koh Boon Hwee,has served as the non-Executive Chairperson of Agilent Technologies, Inc. Board since March 2017. As of January 2023, Mr. Koh is the non-Executive Chairman of the Singapore Exchange Ltd. He has been the managing partner of Altara Ventures Pte. Ltd., a venture capital fund, since December 2011. Mr. Koh has served as the non-Executive Chairperson of Sunningdale Tech Ltd., a privately held company, since April 2021. He served as the non-Executive Chairperson of Sunningdale Tech Ltd., a public company, from January 2009 to March 2021 and served as its Executive Chairperson and Chief Executive Officer from July 2005 to January 2009. He served as the non-Executive Chairperson of Far East Orchard Ltd. from April 2013 to April 2022; served as the non-Executive Chairperson of Yeo Hiap Seng Ltd. from April 2010 to December 2019; as Executive Director of MediaRing Limited from February 2002 to August 2009; Chairperson of DBS Bank Ltd. from January 2006 to April 2010; Chairperson of Singapore Airlines from July 2001 to December 2005 and Chairperson of Singapore Telecom from April 1992 to August 2001. Mr. Koh spent fourteen years with Hewlett-Packard Company in its Asia Pacific region.
Padraig McDonnell

Padraig McDonnell,曾担任Agilent Technologies, Inc.自2024年5月起担任总裁兼首席执行官。从2024年2月到2024年5月,他担任高级副总裁、首席运营官和当选首席执行官。从2021年11月到2024年2月,McDonnell先生担任Agilent CrossLab Group的首席商务官兼总裁。从2020年5月到2021年11月,他担任安捷伦高级副总裁和安捷伦CrossLab集团总裁。从2016年11月到2020年4月,他担任Agilent Technologies, Inc.。化学和供应部门的副总裁兼总经理。在此之前,他曾担任Agilent Technologies, Inc.。emai实验室解决方案销售副总裁兼总经理。McDonnell先生此前曾在Agilent和Hewlett-Packard Company担任多个职位。


Padraig McDonnell,has served as Agilent Technologies, Inc. President and Chief Executive Officer since May 2024. From February 2024 to May 2024, he served as Senior Vice President, Chief Operating Officer and CEO-elect. Mr. McDonnell served as Chief Commercial Officer and President, Agilent CrossLab Group from November 2021 to February 2024. From May 2020 to November 2021, he served as Senior Vice President, Agilent and President, Agilent CrossLab Group. From November 2016 to April 2020, he served as Agilent Technologies, Inc. Vice President and General Manager of the Chemistries and Supplies Division. Prior to that, he served as Agilent Technologies, Inc. Vice President and General Manager of EMEAI Laboratory Solutions Sales. Mr. McDonnell has previously held a variety of positions with Agilent and Hewlett-Packard Company.
Padraig McDonnell,曾担任Agilent Technologies, Inc.自2024年5月起担任总裁兼首席执行官。从2024年2月到2024年5月,他担任高级副总裁、首席运营官和当选首席执行官。从2021年11月到2024年2月,McDonnell先生担任Agilent CrossLab Group的首席商务官兼总裁。从2020年5月到2021年11月,他担任安捷伦高级副总裁和安捷伦CrossLab集团总裁。从2016年11月到2020年4月,他担任Agilent Technologies, Inc.。化学和供应部门的副总裁兼总经理。在此之前,他曾担任Agilent Technologies, Inc.。emai实验室解决方案销售副总裁兼总经理。McDonnell先生此前曾在Agilent和Hewlett-Packard Company担任多个职位。
Padraig McDonnell,has served as Agilent Technologies, Inc. President and Chief Executive Officer since May 2024. From February 2024 to May 2024, he served as Senior Vice President, Chief Operating Officer and CEO-elect. Mr. McDonnell served as Chief Commercial Officer and President, Agilent CrossLab Group from November 2021 to February 2024. From May 2020 to November 2021, he served as Senior Vice President, Agilent and President, Agilent CrossLab Group. From November 2016 to April 2020, he served as Agilent Technologies, Inc. Vice President and General Manager of the Chemistries and Supplies Division. Prior to that, he served as Agilent Technologies, Inc. Vice President and General Manager of EMEAI Laboratory Solutions Sales. Mr. McDonnell has previously held a variety of positions with Agilent and Hewlett-Packard Company.
Daniel K. Podolsky

Daniel K. Podolsky, 2008年9月以来,他担任德克萨斯大学西南医学中心(一个领先的学术医疗中心、患者护理提供者和研究机构)的总裁。此前,他还担任Harvard Medical School的Mallinckrodt医学教授和Massachusetts General Hospital的胃肠病学主任。从2005年到2008年,Podolsky博士担任Partners Healthcare System, Inc.(一个致力于患者护理、研究、教学和服务的非营利性医疗保健系统)学术项目的首席学术官和教务长。Podolsky博士是Philip O'Bryan Montgomery, Jr.医学博士,学术管理杰出总统主席,以及Doris and Bryan Wildenthal医学科学杰出主席。他是西南医学基金会董事会成员。


Daniel K. Podolsky,has served as President of the University of Texas Southwestern Medical Center, a leading academic medical center, patient care provider and research institution, since September 2008. Previously Dr. Podolsky also served concurrently as Mallinckrodt Professor of Medicine at Harvard Medical School and the Chief of Gastroenterology at Massachusetts General Hospital. From 2005 to 2008, Dr. Podolsky served as Chief Academic Officer and Faculty Dean, Academic Programs of Partners Healthcare System, Inc., a non-profit health care system committed to patient care, research, teaching and service. Dr. Podolsky holds the Philip O'Bryan Montgomery, Jr., M.D. Distinguished Presidential Chair in Academic Administration, and the Charles Cameron Sprague Distinguished Chair in Biomedical Science. He is a member of the Board of the Southwestern Medical Foundation.
Daniel K. Podolsky, 2008年9月以来,他担任德克萨斯大学西南医学中心(一个领先的学术医疗中心、患者护理提供者和研究机构)的总裁。此前,他还担任Harvard Medical School的Mallinckrodt医学教授和Massachusetts General Hospital的胃肠病学主任。从2005年到2008年,Podolsky博士担任Partners Healthcare System, Inc.(一个致力于患者护理、研究、教学和服务的非营利性医疗保健系统)学术项目的首席学术官和教务长。Podolsky博士是Philip O'Bryan Montgomery, Jr.医学博士,学术管理杰出总统主席,以及Doris and Bryan Wildenthal医学科学杰出主席。他是西南医学基金会董事会成员。
Daniel K. Podolsky,has served as President of the University of Texas Southwestern Medical Center, a leading academic medical center, patient care provider and research institution, since September 2008. Previously Dr. Podolsky also served concurrently as Mallinckrodt Professor of Medicine at Harvard Medical School and the Chief of Gastroenterology at Massachusetts General Hospital. From 2005 to 2008, Dr. Podolsky served as Chief Academic Officer and Faculty Dean, Academic Programs of Partners Healthcare System, Inc., a non-profit health care system committed to patient care, research, teaching and service. Dr. Podolsky holds the Philip O'Bryan Montgomery, Jr., M.D. Distinguished Presidential Chair in Academic Administration, and the Charles Cameron Sprague Distinguished Chair in Biomedical Science. He is a member of the Board of the Southwestern Medical Foundation.
Mala Anand

Mala Anand 自 2019 年 11 月起担任 Microsoft 客户体验企业副总裁。在加入 Microsoft 之前,她于 2016 年 10 月至 2019 年 10 月担任 SAP SE 智能企业解决方案和行业总裁。从 2014 年 7 月至 2016 年 10 月,Ms. Anand 于 2007 年 10 月至 2014 年 6 月担任 Cisco Systems, Inc. 的数据与分析和自动化软件平台组高级副总裁,并担任 Cisco 服务平台组的副总裁兼总经理,她拥有多项技术专利。 在此之前,Anand 女士在软件产品、上市、服务和技术业务方面担任过多个高级管理职位,并曾担任风险投资公司 Kleiner Perkins Caufield and Byers 的常驻企业家。 她拥有马萨诸塞大学计算机科学学士学位和布朗大学计算机科学硕士学位。


Mala Anand,has served as Corporate Vice President, Customer Experience of Microsoft since November 2019. Prior to joining Microsoft, she served as President, Intelligent Enterprise Solutions and Industries of SAP SE from October 2016 to October 2019. Ms. Anand served as Senior Vice President, Data & Analytics and Automation Software Platform group at Cisco Systems, Inc. from July 2014 to October 2016 and as Vice President and General Manager, Services Platform Group at Cisco from October 2007 to June 2014, and she holds multiple technology patents. Prior to that, Ms. Anand held various senior executive positions in software products, go-to-market, services, and technology businesses and served as entrepreneur in residence for Kleiner Perkins Caufield and Byers, a venture capital firm.
Mala Anand 自 2019 年 11 月起担任 Microsoft 客户体验企业副总裁。在加入 Microsoft 之前,她于 2016 年 10 月至 2019 年 10 月担任 SAP SE 智能企业解决方案和行业总裁。从 2014 年 7 月至 2016 年 10 月,Ms. Anand 于 2007 年 10 月至 2014 年 6 月担任 Cisco Systems, Inc. 的数据与分析和自动化软件平台组高级副总裁,并担任 Cisco 服务平台组的副总裁兼总经理,她拥有多项技术专利。 在此之前,Anand 女士在软件产品、上市、服务和技术业务方面担任过多个高级管理职位,并曾担任风险投资公司 Kleiner Perkins Caufield and Byers 的常驻企业家。 她拥有马萨诸塞大学计算机科学学士学位和布朗大学计算机科学硕士学位。
Mala Anand,has served as Corporate Vice President, Customer Experience of Microsoft since November 2019. Prior to joining Microsoft, she served as President, Intelligent Enterprise Solutions and Industries of SAP SE from October 2016 to October 2019. Ms. Anand served as Senior Vice President, Data & Analytics and Automation Software Platform group at Cisco Systems, Inc. from July 2014 to October 2016 and as Vice President and General Manager, Services Platform Group at Cisco from October 2007 to June 2014, and she holds multiple technology patents. Prior to that, Ms. Anand held various senior executive positions in software products, go-to-market, services, and technology businesses and served as entrepreneur in residence for Kleiner Perkins Caufield and Byers, a venture capital firm.
Otis W. Brawley

Otis W. Brawley,自2019年以来一直担任约翰霍普金斯大学肿瘤学和流行病学彭博杰出教授。布劳利博士从2007年到2018年担任美国癌症协会的首席医疗和科学官。2001年至2018年,他在埃默里大学担任内科医生和肿瘤学家以及血液学、肿瘤学、医学和流行病学教授。布劳利博士自2021年9月起担任Incyte Corporation(一家公共生物技术公司)的董事会成员。他曾担任Lyell Immunopharma, Inc.(公共生物技术公司)的董事会成员(2021年4月以来)。自2020年11月以来,他一直担任PDS Biotechnology Corp(一家上市生物技术公司)的董事会成员。


Otis W. Brawley,has served as a Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University since January 2019. From April 2007 to December 2018, Dr. Brawley served as the Chief Medical and Scientific Officer of the American Cancer Society. From January 2002 to August 2007, Dr. Brawley was director of the Georgia Cancer Center at Grady Memorial Hospital. From April 2001 to December 2018, Dr. Brawley served as Professor of hematology, oncology, medicine and epidemiology at Emory University. Prior to joining Emory University, Dr. Brawley was an assistant director and senior investigator at the National Cancer Institute and an internist and oncologist at the National Institutes of Health Clinical Center and Bethesda Naval Hospital.
Otis W. Brawley,自2019年以来一直担任约翰霍普金斯大学肿瘤学和流行病学彭博杰出教授。布劳利博士从2007年到2018年担任美国癌症协会的首席医疗和科学官。2001年至2018年,他在埃默里大学担任内科医生和肿瘤学家以及血液学、肿瘤学、医学和流行病学教授。布劳利博士自2021年9月起担任Incyte Corporation(一家公共生物技术公司)的董事会成员。他曾担任Lyell Immunopharma, Inc.(公共生物技术公司)的董事会成员(2021年4月以来)。自2020年11月以来,他一直担任PDS Biotechnology Corp(一家上市生物技术公司)的董事会成员。
Otis W. Brawley,has served as a Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University since January 2019. From April 2007 to December 2018, Dr. Brawley served as the Chief Medical and Scientific Officer of the American Cancer Society. From January 2002 to August 2007, Dr. Brawley was director of the Georgia Cancer Center at Grady Memorial Hospital. From April 2001 to December 2018, Dr. Brawley served as Professor of hematology, oncology, medicine and epidemiology at Emory University. Prior to joining Emory University, Dr. Brawley was an assistant director and senior investigator at the National Cancer Institute and an internist and oncologist at the National Institutes of Health Clinical Center and Bethesda Naval Hospital.
George A. Scangos

George A. Scangos自从1996年10月担任董事。自2010年7月Scangos博士担任iogen Idec Inc的首席执行官以及董事会成员。从1996年10月到2010年7月,Scangos博士担任总裁以及首席执行官。从1993年9月到1996年10月,Scangos博士担任拜耳生物科技公司(Bayer Corporation)总裁,该公司是一家制药企业,公司主要负责药物的研究、贸易和过程发展、生产制造、工程管理以及质量保证。Scangos博士在多家上市公司董事会担任成员,包括从2003年到2010年在Anadys制药股份有限公司任职,从1997年到2010年在Entelos股份有限公司任职。Scangos博士还在公司之前的子公司,即TaconicArtemis股份有限公司,任职,在2010年前该公司被称为Artemis制药股份有限公司。Scangos博士曾担任加利福尼亚保健协会(CHI)主席、肺结核药物发展计划全球联盟董事会成员、以及BayBio公司董事会主席。Scangos博士现在担任桑特基金会董事;Scangos博士还是加利福尼亚大学和旧金山制药学院董事会成员,以及加利福尼亚大学和戴维斯医学院国家咨询委员会成员。Scangos博士是耶鲁大学Jane Coffin Childs基金博士后奖学金获得者,同时在霍普金斯大学任教。Scangos博士现持有霍普金斯大学生物学兼职教授的任命书。Scangos博士持有康乃尔大学生物学学士学位,以及马赛诸塞大学微生物博士学位。


George A. Scangos,retired as Chief Executive Officer of Vir Biotechnology in April 2023. He has served as a director of Vir Biotechnology, Inc. since January 2017. Dr. Scangos has also served on the Board of Directors of Voyager Therapeutics, Inc. since May 2023. He is a co-founder and the Chairperson of the Board of Rezo Therapeutics, Inc. since May 2023. From July 2010 to January 2017, Dr. Scangos served as the Chief Executive Officer and is a member of the Board of Directors of Biogen Inc., a biopharmaceutical company. From 1996 to July 2010, Dr. Scangos served as the President and Chief Executive Officer of Exelixis, Inc., a drug discovery and development company. From 1993 to 1996, Dr. Scangos served as President of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer's biological products. Before joining Bayer in 1987, Dr. Scangos was a Professor of Biology at Johns Hopkins University for six years. Dr. Scangos served as the Chair of the California Healthcare Institute in 2010 and was a member of the Board of the Global Alliance for TB Drug Development from 2006 until 2010. He serves on the Board of Advisors of the University of California, San Francisco and is currently an Adjunct Professor of Biology at Johns Hopkins University.
George A. Scangos自从1996年10月担任董事。自2010年7月Scangos博士担任iogen Idec Inc的首席执行官以及董事会成员。从1996年10月到2010年7月,Scangos博士担任总裁以及首席执行官。从1993年9月到1996年10月,Scangos博士担任拜耳生物科技公司(Bayer Corporation)总裁,该公司是一家制药企业,公司主要负责药物的研究、贸易和过程发展、生产制造、工程管理以及质量保证。Scangos博士在多家上市公司董事会担任成员,包括从2003年到2010年在Anadys制药股份有限公司任职,从1997年到2010年在Entelos股份有限公司任职。Scangos博士还在公司之前的子公司,即TaconicArtemis股份有限公司,任职,在2010年前该公司被称为Artemis制药股份有限公司。Scangos博士曾担任加利福尼亚保健协会(CHI)主席、肺结核药物发展计划全球联盟董事会成员、以及BayBio公司董事会主席。Scangos博士现在担任桑特基金会董事;Scangos博士还是加利福尼亚大学和旧金山制药学院董事会成员,以及加利福尼亚大学和戴维斯医学院国家咨询委员会成员。Scangos博士是耶鲁大学Jane Coffin Childs基金博士后奖学金获得者,同时在霍普金斯大学任教。Scangos博士现持有霍普金斯大学生物学兼职教授的任命书。Scangos博士持有康乃尔大学生物学学士学位,以及马赛诸塞大学微生物博士学位。
George A. Scangos,retired as Chief Executive Officer of Vir Biotechnology in April 2023. He has served as a director of Vir Biotechnology, Inc. since January 2017. Dr. Scangos has also served on the Board of Directors of Voyager Therapeutics, Inc. since May 2023. He is a co-founder and the Chairperson of the Board of Rezo Therapeutics, Inc. since May 2023. From July 2010 to January 2017, Dr. Scangos served as the Chief Executive Officer and is a member of the Board of Directors of Biogen Inc., a biopharmaceutical company. From 1996 to July 2010, Dr. Scangos served as the President and Chief Executive Officer of Exelixis, Inc., a drug discovery and development company. From 1993 to 1996, Dr. Scangos served as President of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer's biological products. Before joining Bayer in 1987, Dr. Scangos was a Professor of Biology at Johns Hopkins University for six years. Dr. Scangos served as the Chair of the California Healthcare Institute in 2010 and was a member of the Board of the Global Alliance for TB Drug Development from 2006 until 2010. He serves on the Board of Advisors of the University of California, San Francisco and is currently an Adjunct Professor of Biology at Johns Hopkins University.
Mikael Dolsten

Mikael Dolsten,自2023年7月起担任Pfizer研发公司的首席科学官和总裁。从2019年1月到2023年7月,担任全球研究、开发和医疗的首席科学官兼总裁。2010年12月至2018年12月担任全球研发总裁。高级副总裁;2010年5月至2010年12月担任全球研发总裁。高级副总裁;2009年10月至2010年5月担任Pfizer生物治疗研究与开发集团总裁。Agilent Technologies, Inc 。和Vimian Group AB的董事。


Mikael Dolsten,served as President of Worldwide Research, Development and Medical, Chief Scientific Officer and Executive Vice President of Pfizer, Inc. from 2010 to January 2025 and currently serves as an advisor to the CEO. In July 2024, Dr. Dolsten announced his retirement from Pfizer to occur sometime in 2025. He has served as President of Worldwide Research and Development and Senior Vice President of Pfizer from May 2010 until December 2010 and President of Pfizer BioTherapeutics Research & Development Group and Senior Vice President of Pfizer from 2009 until 2010. From 2008 to 2009, Dr. Dolsten served as Senior Vice President of Wyeth Pharmaceuticals, Inc., a public biopharmaceutical company that was acquired by Pfizer in 2009, and President of Wyeth Research from 2008 to 2009. Prior to joining Wyeth, Dr. Dolsten was a Private Equity Partner at Orbimed Advisors, LLC and Executive Vice President, Head of Pharma Research at Boehringer Ingelheim, a pharmaceutical company. Dr. Dolsten also previously held research leadership positions at AstraZeneca plc, Pharmacia and Upjohn Company. Dr. Dolsten served on the Board of Directors of Karyopharm Therapeutics Inc., a public pharmaceutical company from March 2015 to December 2021. Dr. Dolsten has served on the Board of Directors of Vimian Group, a public company supporting veterinary professionals, since April 2021.
Mikael Dolsten,自2023年7月起担任Pfizer研发公司的首席科学官和总裁。从2019年1月到2023年7月,担任全球研究、开发和医疗的首席科学官兼总裁。2010年12月至2018年12月担任全球研发总裁。高级副总裁;2010年5月至2010年12月担任全球研发总裁。高级副总裁;2009年10月至2010年5月担任Pfizer生物治疗研究与开发集团总裁。Agilent Technologies, Inc 。和Vimian Group AB的董事。
Mikael Dolsten,served as President of Worldwide Research, Development and Medical, Chief Scientific Officer and Executive Vice President of Pfizer, Inc. from 2010 to January 2025 and currently serves as an advisor to the CEO. In July 2024, Dr. Dolsten announced his retirement from Pfizer to occur sometime in 2025. He has served as President of Worldwide Research and Development and Senior Vice President of Pfizer from May 2010 until December 2010 and President of Pfizer BioTherapeutics Research & Development Group and Senior Vice President of Pfizer from 2009 until 2010. From 2008 to 2009, Dr. Dolsten served as Senior Vice President of Wyeth Pharmaceuticals, Inc., a public biopharmaceutical company that was acquired by Pfizer in 2009, and President of Wyeth Research from 2008 to 2009. Prior to joining Wyeth, Dr. Dolsten was a Private Equity Partner at Orbimed Advisors, LLC and Executive Vice President, Head of Pharma Research at Boehringer Ingelheim, a pharmaceutical company. Dr. Dolsten also previously held research leadership positions at AstraZeneca plc, Pharmacia and Upjohn Company. Dr. Dolsten served on the Board of Directors of Karyopharm Therapeutics Inc., a public pharmaceutical company from March 2015 to December 2021. Dr. Dolsten has served on the Board of Directors of Vimian Group, a public company supporting veterinary professionals, since April 2021.
Dow R. Wilson

Dow R. Wilson,自2012年9月起担任瓦里安医疗系统公司董事,自2012年9月起担任总裁兼首席执行官。2011年10月至2012年9月担任执行副总裁兼首席营运官,2005年8月至2011年9月担任公司负责肿瘤系统的执行副总裁和总裁。2005年1月至2005年8月,担任公司负责肿瘤系统的副总裁和总裁。2005年1月加入瓦里安医疗系统公司之前,曾在通用电气(一家多元化的工业公司)中担任高级管理职务。是萨巴软件公司(电子学习软件供应商)的董事会成员。


Dow R. Wilson,was appointed to serve on the Board of Directors of Siemens Healthineers AG in February 2023. He retired as President and Chief Executive Officer of Varian Medical Systems, Inc. in April 2021, a position he held since September 2012. Prior to that, Mr. Wilson served in various capacities with Varian, including Executive Vice President and Chief Operating Officer from October 2011 to September 2012 and Vice President, Varian Medical and President of Varian Medical Oncology Systems business from January 2005 to September 2011. Prior to joining Varian Medical in 2005, Mr. Wilson held various senior management positions with GE Healthcare, a diversified industrial company.
Dow R. Wilson,自2012年9月起担任瓦里安医疗系统公司董事,自2012年9月起担任总裁兼首席执行官。2011年10月至2012年9月担任执行副总裁兼首席营运官,2005年8月至2011年9月担任公司负责肿瘤系统的执行副总裁和总裁。2005年1月至2005年8月,担任公司负责肿瘤系统的副总裁和总裁。2005年1月加入瓦里安医疗系统公司之前,曾在通用电气(一家多元化的工业公司)中担任高级管理职务。是萨巴软件公司(电子学习软件供应商)的董事会成员。
Dow R. Wilson,was appointed to serve on the Board of Directors of Siemens Healthineers AG in February 2023. He retired as President and Chief Executive Officer of Varian Medical Systems, Inc. in April 2021, a position he held since September 2012. Prior to that, Mr. Wilson served in various capacities with Varian, including Executive Vice President and Chief Operating Officer from October 2011 to September 2012 and Vice President, Varian Medical and President of Varian Medical Oncology Systems business from January 2005 to September 2011. Prior to joining Varian Medical in 2005, Mr. Wilson held various senior management positions with GE Healthcare, a diversified industrial company.
Sue H. Rataj

Sue H. Rataj,女,2008年4月到2011年4月带着与英国石油公司的石油化工业务的全球责任退休期间,她是英国石油公司,(一家全球能源公司)的石油化学产品的首席执行官。在这之前,2007年7月到2008年4月,她在英国石油公司担任了许多高级管理职位,最近是炼油与销售部的小组副总裁。她也是拜耳集团,(一家医疗保健、营养和高科技材料领域的有着核心竞争力的全球企业)的监察委员会成员。在她在英国石油公司的事业期间,她获得了安全和风险管理、会计和财务事务,特别是化学公司的背景的意义重大专业知识。


Sue H. Rataj,was a member of the Board of Directors of Cabot Corporation from September 2011 to May 2024. She retired as the non-Executive Chairman of the Board in October 2023. She was Chief Executive, Petrochemicals for BP, a global energy company, until she retired in April 2011. In this role, she held responsibility for all of BP's global petrochemical operations. Prior thereto, Ms. Rataj held a variety of senior management positions with BP, most recently serving as Group Vice President, Health, Safety, Operations and Technology for the Refining and Marketing Segment.
Sue H. Rataj,女,2008年4月到2011年4月带着与英国石油公司的石油化工业务的全球责任退休期间,她是英国石油公司,(一家全球能源公司)的石油化学产品的首席执行官。在这之前,2007年7月到2008年4月,她在英国石油公司担任了许多高级管理职位,最近是炼油与销售部的小组副总裁。她也是拜耳集团,(一家医疗保健、营养和高科技材料领域的有着核心竞争力的全球企业)的监察委员会成员。在她在英国石油公司的事业期间,她获得了安全和风险管理、会计和财务事务,特别是化学公司的背景的意义重大专业知识。
Sue H. Rataj,was a member of the Board of Directors of Cabot Corporation from September 2011 to May 2024. She retired as the non-Executive Chairman of the Board in October 2023. She was Chief Executive, Petrochemicals for BP, a global energy company, until she retired in April 2011. In this role, she held responsibility for all of BP's global petrochemical operations. Prior thereto, Ms. Rataj held a variety of senior management positions with BP, most recently serving as Group Vice President, Health, Safety, Operations and Technology for the Refining and Marketing Segment.

高管简历

中英对照 |  中文 |  英文
Padraig McDonnell

Padraig McDonnell,曾担任Agilent Technologies, Inc.自2024年5月起担任总裁兼首席执行官。从2024年2月到2024年5月,他担任高级副总裁、首席运营官和当选首席执行官。从2021年11月到2024年2月,McDonnell先生担任Agilent CrossLab Group的首席商务官兼总裁。从2020年5月到2021年11月,他担任安捷伦高级副总裁和安捷伦CrossLab集团总裁。从2016年11月到2020年4月,他担任Agilent Technologies, Inc.。化学和供应部门的副总裁兼总经理。在此之前,他曾担任Agilent Technologies, Inc.。emai实验室解决方案销售副总裁兼总经理。McDonnell先生此前曾在Agilent和Hewlett-Packard Company担任多个职位。


Padraig McDonnell,has served as Agilent Technologies, Inc. President and Chief Executive Officer since May 2024. From February 2024 to May 2024, he served as Senior Vice President, Chief Operating Officer and CEO-elect. Mr. McDonnell served as Chief Commercial Officer and President, Agilent CrossLab Group from November 2021 to February 2024. From May 2020 to November 2021, he served as Senior Vice President, Agilent and President, Agilent CrossLab Group. From November 2016 to April 2020, he served as Agilent Technologies, Inc. Vice President and General Manager of the Chemistries and Supplies Division. Prior to that, he served as Agilent Technologies, Inc. Vice President and General Manager of EMEAI Laboratory Solutions Sales. Mr. McDonnell has previously held a variety of positions with Agilent and Hewlett-Packard Company.
Padraig McDonnell,曾担任Agilent Technologies, Inc.自2024年5月起担任总裁兼首席执行官。从2024年2月到2024年5月,他担任高级副总裁、首席运营官和当选首席执行官。从2021年11月到2024年2月,McDonnell先生担任Agilent CrossLab Group的首席商务官兼总裁。从2020年5月到2021年11月,他担任安捷伦高级副总裁和安捷伦CrossLab集团总裁。从2016年11月到2020年4月,他担任Agilent Technologies, Inc.。化学和供应部门的副总裁兼总经理。在此之前,他曾担任Agilent Technologies, Inc.。emai实验室解决方案销售副总裁兼总经理。McDonnell先生此前曾在Agilent和Hewlett-Packard Company担任多个职位。
Padraig McDonnell,has served as Agilent Technologies, Inc. President and Chief Executive Officer since May 2024. From February 2024 to May 2024, he served as Senior Vice President, Chief Operating Officer and CEO-elect. Mr. McDonnell served as Chief Commercial Officer and President, Agilent CrossLab Group from November 2021 to February 2024. From May 2020 to November 2021, he served as Senior Vice President, Agilent and President, Agilent CrossLab Group. From November 2016 to April 2020, he served as Agilent Technologies, Inc. Vice President and General Manager of the Chemistries and Supplies Division. Prior to that, he served as Agilent Technologies, Inc. Vice President and General Manager of EMEAI Laboratory Solutions Sales. Mr. McDonnell has previously held a variety of positions with Agilent and Hewlett-Packard Company.
Rodney Gonsalves

Rodney Gonsalves,自2015年5月起担任公司的副总裁、公司财务控制和会计总监。2009年9月-2015年5月他担任公司不同业务部门(目前在Life Sciences and Applied Markets Group)的副总裁和运营财务总监。2007年1月-2009年8月他担任Investor Relations的副总裁。在担任这个职位之前,他在 Agilent担任不同的职位,包括在Agilent的全球基础设施组织中担任财务总监、公司治理和客户融资,也在光电系统业务部担任财务总监。在加入Agilent之前,他在Hewlett- Packard Co.担任各种各样的职位。Gonsalves先生拥有加州圣克拉拉大学(Santa Clara University in California)工商管理硕士学位。


Rodney Gonsalves,served as Vice President and operational CFO for various business groups within the company, most recently for the Life Sciences and Applied Markets Group. Prior to that, Mr. Gonsalves served in various capacities for Agilent, including as vice president of Investor Relations, controller, corporate governance and customer financing in Agilent's Global Infrastructure Organization, and controller for the Photonics Systems Business Unit. Before joining Agilent, Mr. Gonsalves held a variety of positions in finance with Hewlett-Packard Company.
Rodney Gonsalves,自2015年5月起担任公司的副总裁、公司财务控制和会计总监。2009年9月-2015年5月他担任公司不同业务部门(目前在Life Sciences and Applied Markets Group)的副总裁和运营财务总监。2007年1月-2009年8月他担任Investor Relations的副总裁。在担任这个职位之前,他在 Agilent担任不同的职位,包括在Agilent的全球基础设施组织中担任财务总监、公司治理和客户融资,也在光电系统业务部担任财务总监。在加入Agilent之前,他在Hewlett- Packard Co.担任各种各样的职位。Gonsalves先生拥有加州圣克拉拉大学(Santa Clara University in California)工商管理硕士学位。
Rodney Gonsalves,served as Vice President and operational CFO for various business groups within the company, most recently for the Life Sciences and Applied Markets Group. Prior to that, Mr. Gonsalves served in various capacities for Agilent, including as vice president of Investor Relations, controller, corporate governance and customer financing in Agilent's Global Infrastructure Organization, and controller for the Photonics Systems Business Unit. Before joining Agilent, Mr. Gonsalves held a variety of positions in finance with Hewlett-Packard Company.
Simon May

Simon May,2022年1月至2024年5月,担任Bio-Rad Laboratories(“Bio-Rad”)执行副总裁兼生命科学集团总裁。在Bio-Rad任职的10年期间,May先生担任过多个领导职务,包括2020年1月至2021年12月担任高级副总裁、数字生物集团总经理,以及2015年10月至2020年1月担任全球商业运营高级副总裁。在2014年加入Bio-Rad之前,May先生曾在赛默飞世尔任职10年。


Simon May,served as Executive Vice President and President of the Life Science Group at Bio-Rad Laboratories ("Bio-Rad") from January 2022 to May 2024. During his 10-year tenure at Bio-Rad, Mr. May held various leadership roles including that of Senior Vice President, General Manager of the Digital Biology Group from January 2020 to December 2021 and as Senior Vice President of Global Commercial Operations from October 2015 to January 2020. Before joining Bio-Rad in 2014, Mr. May held positions at Thermo Fisher Scientific for 10 years.
Simon May,2022年1月至2024年5月,担任Bio-Rad Laboratories(“Bio-Rad”)执行副总裁兼生命科学集团总裁。在Bio-Rad任职的10年期间,May先生担任过多个领导职务,包括2020年1月至2021年12月担任高级副总裁、数字生物集团总经理,以及2015年10月至2020年1月担任全球商业运营高级副总裁。在2014年加入Bio-Rad之前,May先生曾在赛默飞世尔任职10年。
Simon May,served as Executive Vice President and President of the Life Science Group at Bio-Rad Laboratories ("Bio-Rad") from January 2022 to May 2024. During his 10-year tenure at Bio-Rad, Mr. May held various leadership roles including that of Senior Vice President, General Manager of the Digital Biology Group from January 2020 to December 2021 and as Senior Vice President of Global Commercial Operations from October 2015 to January 2020. Before joining Bio-Rad in 2014, Mr. May held positions at Thermo Fisher Scientific for 10 years.
Bret DiMarco

Bret DiMarco,于2022年9月至2024年6月期间担任私人控股公司Pendo.io Incorporated的首席法务官。2006年6月至2022年7月,他曾在Coherent, Inc.担任多个职位,包括执行副总裁、总法律顾问、首席法务官和公司秘书,直到该公司被II-VI公司收购,之后他担任总裁特别顾问至2022年9月。自2004年9月以来,DiMarco先生一直担任旧金山加州大学法学院的兼职法学副教授。2023年10月至今,DiMarco先生担任Nasdaq交易所提名委员会主席和Nasdaq交易所审查委员会成员。DiMarco先生之前是跨国律师事务所Wilson Sonsini Goodrich & Rosati,P.C。的成员和合伙人。


Bret DiMarco,served as the Chief Legal Officer at Pendo.io Incorporated, a privately held company, from September 2022 to June 2024. From June 2006 to July 2022, he held several positions at Coherent, Inc., including Executive Vice President, General Counsel, Chief Legal Officer and Corporate Secretary until its acquisition by II-VI Incorporated after which he served as a Special Advisor to the President until September 2022. Since September 2004, Mr. DiMarco has been an Adjunct Associate Professor of Law at the University of California College of the Law, San Francisco. From October 2023 to present, Mr. DiMarco has been the Chair of the Nasdaq Exchange Nominating Committee and a member of the Nasdaq Exchange Review Council. Mr. DiMarco was previously a member and associate at Wilson Sonsini Goodrich & Rosati, P.C., a multinational law firm.
Bret DiMarco,于2022年9月至2024年6月期间担任私人控股公司Pendo.io Incorporated的首席法务官。2006年6月至2022年7月,他曾在Coherent, Inc.担任多个职位,包括执行副总裁、总法律顾问、首席法务官和公司秘书,直到该公司被II-VI公司收购,之后他担任总裁特别顾问至2022年9月。自2004年9月以来,DiMarco先生一直担任旧金山加州大学法学院的兼职法学副教授。2023年10月至今,DiMarco先生担任Nasdaq交易所提名委员会主席和Nasdaq交易所审查委员会成员。DiMarco先生之前是跨国律师事务所Wilson Sonsini Goodrich & Rosati,P.C。的成员和合伙人。
Bret DiMarco,served as the Chief Legal Officer at Pendo.io Incorporated, a privately held company, from September 2022 to June 2024. From June 2006 to July 2022, he held several positions at Coherent, Inc., including Executive Vice President, General Counsel, Chief Legal Officer and Corporate Secretary until its acquisition by II-VI Incorporated after which he served as a Special Advisor to the President until September 2022. Since September 2004, Mr. DiMarco has been an Adjunct Associate Professor of Law at the University of California College of the Law, San Francisco. From October 2023 to present, Mr. DiMarco has been the Chair of the Nasdaq Exchange Nominating Committee and a member of the Nasdaq Exchange Review Council. Mr. DiMarco was previously a member and associate at Wilson Sonsini Goodrich & Rosati, P.C., a multinational law firm.
Jonah Kirkwood

Jonah Kirkwood,从2023年6月到2024年10月,Kirkwood先生领导了安捷伦公司实验室解决方案销售的全球销售组织以及大中华区销售组织。Kirkwood先生于2021年11月至2023年5月期间领导安捷伦科技公司商业营销和运营团队。在此之前,他在安捷伦担任过多个职位。在安捷伦收购瓦里安后,Kirkwood先生于2010年首次加入安捷伦。


Jonah Kirkwood,From June 2023 to October 2024, Mr. Kirkwood led Agilent's Global Sales organization for Laboratory Solution Sales as well as the Greater China Sales organization. Mr. Kirkwood led Agilent Technologies, Inc. Commercial Marketing and Operations teams from November 2021 to May 2023. Prior to that, he held various positions in Agilent. Mr. Kirkwood first joined Agilent in 2010 after Agilent acquired Varian.
Jonah Kirkwood,从2023年6月到2024年10月,Kirkwood先生领导了安捷伦公司实验室解决方案销售的全球销售组织以及大中华区销售组织。Kirkwood先生于2021年11月至2023年5月期间领导安捷伦科技公司商业营销和运营团队。在此之前,他在安捷伦担任过多个职位。在安捷伦收购瓦里安后,Kirkwood先生于2010年首次加入安捷伦。
Jonah Kirkwood,From June 2023 to October 2024, Mr. Kirkwood led Agilent's Global Sales organization for Laboratory Solution Sales as well as the Greater China Sales organization. Mr. Kirkwood led Agilent Technologies, Inc. Commercial Marketing and Operations teams from November 2021 to May 2023. Prior to that, he held various positions in Agilent. Mr. Kirkwood first joined Agilent in 2010 after Agilent acquired Varian.
Angelica A. Reimann

Angelica A. Reimann2021年8月至2024年2月,任安捷伦CrossLab服务事业部副总裁兼总经理。Riemann女士于2020年5月至2021年8月担任副总裁兼化学品和用品事业部总经理。2019年3月至2020年5月,任副总裁兼化学品事业部总经理。在2019年3月之前,她曾在化学部门、质谱部门和美洲实地组织销售组织担任领导职务。


Angelica A. Reimann,From August 2021 to February 2024, she served as Vice President and General Manager of Agilent CrossLab Services Division. Ms. Riemann served as Vice President and General Manager of the Chemistries and Supplies Division from May 2020 to August 2021. From March 2019 to May 2020, she was Vice president and General Manager of the Chemistries Division. Prior to March 2019, she held leadership roles in the Chemistries Division, Mass Spectrometry Division and the Americas Field Organization sales organization.
Angelica A. Reimann2021年8月至2024年2月,任安捷伦CrossLab服务事业部副总裁兼总经理。Riemann女士于2020年5月至2021年8月担任副总裁兼化学品和用品事业部总经理。2019年3月至2020年5月,任副总裁兼化学品事业部总经理。在2019年3月之前,她曾在化学部门、质谱部门和美洲实地组织销售组织担任领导职务。
Angelica A. Reimann,From August 2021 to February 2024, she served as Vice President and General Manager of Agilent CrossLab Services Division. Ms. Riemann served as Vice President and General Manager of the Chemistries and Supplies Division from May 2020 to August 2021. From March 2019 to May 2020, she was Vice president and General Manager of the Chemistries Division. Prior to March 2019, she held leadership roles in the Chemistries Division, Mass Spectrometry Division and the Americas Field Organization sales organization.
Mike Zhang

Mike Zhang,2024年8月至11月,在原生命科学与应用市场集团内担任副总裁兼气相事业部总经理。在此之前,Zhang先生于2020年1月至2024年8月担任气相分离事业部副总裁兼总经理。此前,他在安捷伦22年的时间里,曾在制造业担任过各种领导职务。2002年3月至2019年12月,他在安捷伦上海工厂担任制造工程师。他还在安捷伦的订单履行和供应链组织中担任过各种领导职务,并于2016年4月被任命为GC运营全球制造经理和安捷伦上海站点总经理。


Mike Zhang,From August to November 2024, he served as Vice President and General Manager of the Gas Phase Division within the former Life Sciences and Applied Markets Group. Prior to that, Mr. Zhang was Vice President and General Manager for the Gas Phase Separations Division from January 2020 to August 2024. He previously held various leadership roles in manufacturing over the span of his 22 years at Agilent. He was a manufacturing engineer at Agilent's Shanghai site from March 2002 to December 2019. He also held various leadership roles in Agilent's Order Fulfillment and Supply Chain organization and was named global manufacturing manager for GC operations and general manager of Agilent's Shanghai site in April 2016.
Mike Zhang,2024年8月至11月,在原生命科学与应用市场集团内担任副总裁兼气相事业部总经理。在此之前,Zhang先生于2020年1月至2024年8月担任气相分离事业部副总裁兼总经理。此前,他在安捷伦22年的时间里,曾在制造业担任过各种领导职务。2002年3月至2019年12月,他在安捷伦上海工厂担任制造工程师。他还在安捷伦的订单履行和供应链组织中担任过各种领导职务,并于2016年4月被任命为GC运营全球制造经理和安捷伦上海站点总经理。
Mike Zhang,From August to November 2024, he served as Vice President and General Manager of the Gas Phase Division within the former Life Sciences and Applied Markets Group. Prior to that, Mr. Zhang was Vice President and General Manager for the Gas Phase Separations Division from January 2020 to August 2024. He previously held various leadership roles in manufacturing over the span of his 22 years at Agilent. He was a manufacturing engineer at Agilent's Shanghai site from March 2002 to December 2019. He also held various leadership roles in Agilent's Order Fulfillment and Supply Chain organization and was named global manufacturing manager for GC operations and general manager of Agilent's Shanghai site in April 2016.
Adam S. Elinoff

Adam S. Elinoff,自2025年7月起担任全球生物技术公司Amgen Inc.(“Amgen”)的副总裁、投资者关系和财务主管。Elinoff先生于2006年加入Amgen,担任过一系列财务、战略、转型方面的角色,职责与日俱增。2023年至2025年7月,Elinoff先生担任副总裁、财务和财务主管。2020年至2023年,担任欧洲、中东、非洲、拉丁美洲、加拿大区域首席财务官。2017年至2020年,任执行董事兼企业财务规划与分析主管。Elinoff先生拥有Arizona State大学W. P. Carey商学院的工商管理硕士学位和Hamilton学院的经济学文学学士学位。


Adam S. Elinoff,has served as Vice President, Investor Relations and Treasurer of Amgen Inc. ("Amgen"), a global biotechnology company, since July 2025. Mr. Elinoff joined Amgen in 2006 and has held a series of finance, strategy, and transformation roles of increasing responsibility. From 2023 to July 2025, Mr. Elinoff served as Vice President, Finance and Treasurer. From 2020 to 2023, he served as Regional Chief Financial Officer for Europe, Middle East, Africa, Latin America, and Canada. From 2017 to 2020, he served as Executive Director and Head of Corporate Financial Planning and Analysis. Mr. Elinoff holds a Master of Business Administration from the W. P. Carey School of Business at Arizona State University and a Bachelor of Arts degree in Economics from Hamilton College.
Adam S. Elinoff,自2025年7月起担任全球生物技术公司Amgen Inc.(“Amgen”)的副总裁、投资者关系和财务主管。Elinoff先生于2006年加入Amgen,担任过一系列财务、战略、转型方面的角色,职责与日俱增。2023年至2025年7月,Elinoff先生担任副总裁、财务和财务主管。2020年至2023年,担任欧洲、中东、非洲、拉丁美洲、加拿大区域首席财务官。2017年至2020年,任执行董事兼企业财务规划与分析主管。Elinoff先生拥有Arizona State大学W. P. Carey商学院的工商管理硕士学位和Hamilton学院的经济学文学学士学位。
Adam S. Elinoff,has served as Vice President, Investor Relations and Treasurer of Amgen Inc. ("Amgen"), a global biotechnology company, since July 2025. Mr. Elinoff joined Amgen in 2006 and has held a series of finance, strategy, and transformation roles of increasing responsibility. From 2023 to July 2025, Mr. Elinoff served as Vice President, Finance and Treasurer. From 2020 to 2023, he served as Regional Chief Financial Officer for Europe, Middle East, Africa, Latin America, and Canada. From 2017 to 2020, he served as Executive Director and Head of Corporate Financial Planning and Analysis. Mr. Elinoff holds a Master of Business Administration from the W. P. Carey School of Business at Arizona State University and a Bachelor of Arts degree in Economics from Hamilton College.